Skip to main content

ESPRESSO

The ESPRESSO study (Epidemiology Strengthened by histoPathology Reports in Sweden) constitutes a novel approach to examine the aetiology and prognosis of gastrointestinal (GI) disease where histopathology plays a crucial role.

Between 2015-17, all pathology departments (n=28) in Sweden were contacted to obtain histopathology record data from the GI tract (pharynx to anus), liver, gallbladder and pancreas. For each individual, local histopathology IT personnel retrieved data on personal identity number, date of histopathology, topography (where the biopsy was taken), morphology (biopsy appearance), and where available free text. In total, histopathology record data were available in 2.1 million individuals between 1965 and 2017, but the number of data entries (since many individuals had been biopsied more than once) was 6.1 million. A subset of records also contain the free text from the histopathology report. Index individuals with histopathology data have since been matched with up to five controls from the general population, and all first-degree relatives and spouses have been identified. In total, the study population consists of 13.0 million individuals.

Data from all study participants have been linked to Swedish National Healthcare Registers allowing research on such aspects as fetal and perinatal conditions and risk of future GI disease, but also risk of comorbidity, complications (including cancer) and death in GI disease. Furthermore, the ESPRESSO study enables researchers to identify diagnoses and disease phenotypes that are not currently indexed in national registers (including disease precursors), but also to increase sensitivity and specificity of already recorded diseases in the National Health Registers.

Number of biopsy reports (the number of unique individuals is smaller) *includes adenoid tissue. #Using T652 (for ileum) allows for differentiation between jejunum and ileum. § T67 can be further divided into caecum, pars ascendens, right flexure, transverse, left flexure, descendens and the sigmoid.

Figure 2 is restricted to years with ≥100,000 histopathology reports per year. 1986-1999 the number of annual records was 50,000-<100,000.

Combining topography and morphology codes allows researchers to identify specific diseases. ESPRESSO can also be used to identify unspecific findings in a particular location (for instance 893,117 unique individuals have a colorectal histopathology report; 179,110 have a liver histopathology report, and the database contains 492,413 unique individuals with a normal small intestinal mucosa).

Study personnel

Jonas Ludvigsson

Telefon:08-524 823 56

E-post:Jonas.Ludvigsson@ki.se

Mariam Lashkariani

Telefon:08-524 823 16

E-post:Mariam.Lashkariani@ki.se

Bjorn Roelstraete

Telefon:08-524 823 09

E-post:bjorn.roelstraete@ki.se

 

Collaborators

Amit Joshi

Department of Epidemiology,
Harvard T.H. Chan School of Public Health

Research interest: I am interested in looking at the incidence of different health outcomes after cholecystectomy. Initially, I will examine whether undergoing cholecystectomy is associated with short and long-term mortality.

Hamed Khalili

Assistant Professor at Harvard Medical School and Crohn’s and Colitis Center, Massachusetts General Hospital

Research interest: As a gastroenterologist, I am dedicated to clinical and translational investigations of inflammatory bowel diseases. To date, my research has focused on understanding and defining environmental predictors, such as diet, reproductive, and lifestyle factors, and their interplay with common genetic risk loci and the gut microbial environment, on risk and progression of inflammatory bowel disorders.

Benjamin Lebwohl

Departments of Medicine and Epidemiology, Celiac Disease Center, Columbia University

I am a gastroenterologist and clinical researcher with a primary focus on celiac disease and gluten-related disorders. I have investigated risk factors, long-term outcomes, and practice patterns in celiac disease. I am also investigating the changing mortality risk in this condition over time. My secondary focus is on colorectal cancer prevention, with an emphasis on colonoscopy quality.

Long Nguyen

Department of Epidemiology,
Harvard T.H. Chan School of Public Health

I am interested in combining traditional epidemiological methods with translational approaches to answer questions related to nutrition, dysbiosis, colorectal cancer, and inflammatory bowel disease.

Mingyang Song

Department of Epidemiology,
Harvard T.H. Chan School of Public Health

The goal of my project is to examine the long-term risk of developing and dying from colorectal cancer in individuals with sessile serrated adenoma/polyp (SSA/P), a newly recognized precursor lesion for colorectal cancer.

Tracey Simon

Department of Epidemiology, Harvard T.H. Chan School of Public Health

I am examining the association between commonly-used medications (aspirin, statins) and clinical outcomes in patients with biopsy-proven nonalcoholic fatty liver disease.

Kyle Staller

Department of Epidemiology,
Harvard T.H. Chan School of Public Health

I am examining the relationship between irritable bowel syndrome (IBS) and outcomes more traditionally associated with non-functional GI disorders such as mortality.

PhD students

David Bergman

E-post:david.bergman.1@ki.se

 

Publication

Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden).
Ludvigsson JF, Lashkariani M
Clin Epidemiol 2019 ;11():101-114

Please go to "documents" for the pdf version of the publication.

Documents